Antonio Passaro: COCOON study meets primary endpoint
Antonio Passaro, Lung cancer oncologist & researcher at Instituto Europeo di Oncologia, shared a post on X:
“COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatologic reactions with easy-to-use prophylactic regimen for patients with EGFR-mutated NSCLC.“
Antonio Passaro, MD PhD, is a Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology in Milan, specialising in lung cancer research and treatment. He focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC). Dr. Antonio Passaro is an Associate Editor for Lung Cancer Journal by Elsevier and the Chair of the ESMO Press and Media Affairs Committee. He is also a faculty member for the Lung and Other Thoracic Tumours faculty group and the ESMO-MCBS Extended Working Group. He also holds editorial positions and key roles in societies like ESMO and AIOM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023